IMMX Projected Dividend Yield

Immix Biopharma Inc ( NASDAQ : IMMX )

Immix Biopharma is a clinical-stage biopharmaceutical company engaged in the development of a class of Tissue-Specific Therapeutics (TSTx)™ in oncology and inflammation. Co.'s primary asset, IMX-110, is for the treatment of solid tumors. IMX-110 is a negatively-charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor and induces tumor cell death with an apoptosis inducer, utilizing Co.'s TME Normalization™ Technology, delivered deep into the tumor micro-environment (TME). Co.'s TME Normalization™ Technology allows its drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME.

20 YEAR PERFORMANCE RESULTS